VANCOUVER, British Columbia, November 25, 2025 – TheNewswire - BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company, focused on development of BETR-001, its proprietary non-hallucinogenic derivative of LSD. BetterLife is pleased to announce Daniel Carcillo will join the Company as Corporate Advisor to advance BetterLife’s BETR-001 development with focus on Traumatic Brain Injury (“TBI”), cluster headache and migraine.

 

Mr. Carcillo is a Canadian former professional hockey left winger who won two Stanley Cups as a member of the Chicago Blackhawks of the National Hockey League (“NHL”). He was forced to retire at the age of 30 due to Post Concussion Syndrome after seven concussions. After retiring from the NHL in 2015, Mr. Carcillo created a non-profit organization that assists former NHL-players suffering from post-concussion syndrome and mental health issues.  A well-known speaker and advocate on behalf of TBI survivors and people dealing with mental health challenges, Mr. Carcillo was the founder and CEO of Wesana Health, a life sciences company that leverages psilocybin-based medicine to treat traumatic brain injuries.

 

Mr. Carcillo stated, “Joining BetterLife feels like the natural next step in my mission to help concussion survivors because we are advancing a medicine that carries the promise of psychedelic healing without the regulatory barriers and with all the serotonergic benefits people desperately need. I have lived the impact of brain trauma and I know how powerful these breakthroughs can be. This is about giving athletes veterans and anyone living with the invisible weight of concussion a real chance to heal and get their life back."

 

Dr. Ahmad Doroudian, CEO of BetterLife, commented, “We are very excited to have Mr. Carcillo joining our advisory group. His first hand experience with TBI and his passion to advance the development of  medicines and treatments for those injuries will provide us with invaluable guidance. We look forward to working with Daniel to advance the development BETR-001.”

  

About BetterLife Pharma

 

BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing BETR-001 to treat various neurological disorders. BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be self-administered. BetterLife’s synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of various neurological disorders, until around 2042.

 

BetterLife also owns a drug candidate for the treatment of viral infections and is in the process of seeking strategic alternatives for further development.

 

For further information, please visit BetterLife Pharma.

  

Contact

Ahmad Doroudian, Chief Executive Officer

Email:  Ahmad.Doroudian@blifepharma.com  

Phone: 1-604-221-0595

  

Cautionary Note Regarding Forward-Looking Statements

 

No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.